Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Alembic Pharma gets USFDA nod for generic cancer, arthritis injection
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its generic methotrexate injection, used to treat multiple cancers and arthritis conditions. The approval covers key dosage formats and confirms therapeutic equivalence to the reference drug by Hospira, enabling Alembic to market the injectable in the US. Methotrexate is widely used for treating cancers such as leukemia, osteosarcoma and breast cancer, as well as conditions like rheumatoid arthritis and severe psoriasis.
Alembic Pharma shares gain after drugmaker gets USFDA approval for cancer treatment drug
With this approval, Alembic Pharma now has a cumulative total of 236 ANDA approvals from the USFDA, including 218 final approvals and 18 tentative approvals.
Alembic Pharmaceuticals climbs on securing USFDA nod for Dapagliflozin tablet
Alembic Pharmaceuticals surged 3.85% to Rs 681.40 after it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Dapagliflozin tablets in 5 mg and 10 mg strengths.
Alembic Pharma gains 4% on USFDA nod for key diabetes drug
Alembic Pharma gets USFDA nod for generic Dapagliflozin tablets, equivalent to AstraZenecas Farxiga, gaining 180 day shared exclusivity in a $10.49 billion US market
Alembic Pharma gets USFDA nod for generic drug
Alembic Pharmaceuticals has secured approval from the US health regulator for a generic seizure medication. The company received final clearance from the USFDA for Lamotrigine orally disintegrating tablets. This drug is therapeutically equivalent to GlaxoSmithKline's Lamictal. It is used for various seizure types in patients aged two and older. The market for this medication is estimated at USD 27 million.
Alembic Pharma gets USFDA nod for anti-seizure drug but stock sees volatile moves
Lamotrigine is primarily used to treat seizures. According to IQVIA data, the estimated market size for the product is $27 million for the twelve months ending December 2025.
Alembic Pharma completes USFDA inspection at Karakhadi, Gujarat facility with two observations
Shares of Alembic Pharmaceuticals Ltd ended at ₹773.70, down by ₹2.70, or 0.35%, on the BSE.
Stocks to Watch Today: Creative Newtech, HG Infra, Merritronix, EMS, Alembic Pharma, Adani Enterprises, Adani Energy in focus on 08 June
Stocks to Watch, 08 Jun: Stocks like Creative Newtech, HG Infra, Merritronix, EMS, Alembic Pharma, Adani Enterprises, and Adani Energy Solutios will aso be in focus on June 8.
Alembic Pharma targets double-digit growth as US momentum picks up
'We see the US business well set for 10–15 percent growth… driven by launches and share gains,' managing director Pranav Amin tells Moneycontrol
Trade Spotlight: How should you trade Ather Energy, Alembic Pharma, GMR Airports, Gujarat Fluorochemicals, Mankind Pharma, and others on July 1?
The market is likely to remain range-bound as long as it trades below the previous week's high. Below are some short-term trading ideas to consider.
Trade Spotlight: How should you trade Alembic Pharma, Alkyl Amines Chemicals, JSW Infrastructure, Syrma SGS Tech, Greaves Cotton, and others on July 10?
The market is expected to continue its recovery, but a sustained close above Wednesday's high will be crucial for a sharper upmove. Below are some short-term trading ideas to consider.